Navigation Links
Quark Pharmaceuticals Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Delivered siRNA Drug Candidate for Delayed Graft Function
Date:1/8/2009

Kidney transplantation to be Quark's second indication with clinical-stage, systemically administered siRNA product candidate

FREMONT, Calif., Jan. 8 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company discovering and developing novel RNA interference (RNAi)-based therapeutics, today announced that it has initiated patient dosing in its Phase I/II clinical trial evaluating its systemically administered siRNA drug candidate QPI-1002 (previously referred to as DGFi) for prevention of Delayed Graft Function (DGF) in patients undergoing deceased donor kidney transplantation. DGF represents Quark's second indication being evaluated for the systemically administered dug candidate in human clinical trials. This trial follows two currently enrolling Phase I clinical trials in acute kidney injury (AKI).

The multi-center, two-part Phase I/II clinical trial in DGF is expected to enroll up to 204 adult kidney transplant recipients. The first part of the study is a dose-escalation design to evaluate the safety and tolerability of a single intravenous injection of QPI-1002 in renal transplant patients at high risk to develop DGF. The second part of the study will evaluate safety and potential clinical activity of a selected dose of QPI-1002 in the same patient population. Patients will be enrolled in clinical sites in the United States.

Shai Erlich, Ph.D., Chief Medical Officer of Quark, commented, "The initiation of patient dosing with QPI-1002 is an important milestone for Quark as well as being an innovative approach to offer therapeutic benefit to adult kidney transplant patients at high risk for developing DGF. The siRNA drug candidate is based on the proprietary concept of Quark and reflects Quark's success in developing products originating from conceptually novel internal developments. These accomplishments further validate Quark's ability to advance innovative product candida
'/>"/>

SOURCE Quark Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy
2. Quark Pharmaceuticals Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property
3. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
4. Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema
5. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
6. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
7. Quark Pharmaceuticals Appoints New Chief Medical Officer
8. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
9. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...TER,N.J.,Nov.25/PRNewswire/--TheFDAgrantedtraditio...non-nucleosidereversetranscriptaseinhibitor(NNRTI)...eintreatment-experiencedadultswhoareexperiencingvi...dotherantiretroviral(ARV)agents.Thetraditionalappr...sDUET-1andDUET-2.INTELENCEiscurrentlymarketedinthe...
(Date:11/25/2009)...IDGE,N.J.,Nov.25/PRNewswire/--RegadoBiosciences,ap...mboticaptamerswithactivecontrolagents,announcedtha...thePiperJaffray21stAnnualHealthCareConferenceatthe...tionwillbegivenat1:10pm(EST)onTuesday,December1and...hasisontheleaddevelopmentprogram,theanticoagulants...
(Date:11/25/2009)...Y,Calif.,Nov.25/PRNewswire-FirstCall/--Abaxis,Inc....ngpoint-of-carebloodanalysissystems,announcedtoday...,willpresentatthe21stAnnualPiperJaffrayHealthCareC...econferencewillbeheldattheNewYorkPalaceHotelinNewY...manufacturesandmarketsportablebloodanalysissystems...
Breaking Medicine Technology:U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine) 2U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine) 3U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine) 4Regado Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference on December 1, 2009 2Syngenta Acquires Innovative Bio Control Technology to Improve Usable Crop Yields 12574 1Syngenta Acquires Innovative Bio Control Technology to Improve Usable Crop Yields 12574 2Syngenta Acquires Innovative Bio Control Technology to Improve Usable Crop Yields 12574 3A WIT Technologies Releases World 26apos 3Bs First Low Cost C Stamp 28TM 29 Based Biotechnology Laboratory in a Box 12572 1A WIT Technologies Releases World 26apos 3Bs First Low Cost C Stamp 28TM 29 Based Biotechnology Laboratory in a Box 12572 2Polycom and AMD Global Telemedicine Inc To Deliver Integrated Visual And Voice Telehealth Capability To Clinicians On The Go 48554 1Polycom and AMD Global Telemedicine Inc To Deliver Integrated Visual And Voice Telehealth Capability To Clinicians On The Go 48554 2Polycom and AMD Global Telemedicine Inc To Deliver Integrated Visual And Voice Telehealth Capability To Clinicians On The Go 48554 3
...tes Recognized as Marker of,Treatment Success -, ...-conducted study being presented at the 59th Annua...y of Liver Diseases (AASLD) shows that,PEGASYS(R) ...in higher,sustained virological response (SVR) rat...s with another pegylated interferon.(1), Comparin...
...,significantly increase the risk of the most commo...ied by researchers at Massachusetts General,Hospit...November 7th issue,of American Journal of Human Ge...s Genome Project" (AGP) established three years ag...genetic risk factors, may lead to more,aggressive ...
Other Medicine Technology:New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients 2New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients 3New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients 4New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients 5New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients 6New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients 7Breakthrough Mapping of Alzheimer's Genome Helps ID Four New Suspect Genes 2Breakthrough Mapping of Alzheimer's Genome Helps ID Four New Suspect Genes 3
(Date:11/27/2009)...e; announced today that Spectrum Health (Grand Rap...se orthopedic templating solution and its TraumaCa... (PRWEB) November 27, 2009 -- Voyant Health&tr...apids, Michigan) has licensed its TraumaCad Enterp...Cad Extend workflow solution, to allow its orthope...
(Date:11/27/2009)...turers who use medical load cells at the heart of ...ringing in technology partner Flintec early in the...medical manufacturers are calling in Flintec load ...s, ensuring that progress will not be constrained ...ed technology. , (PRWEB) ...
(Date:11/26/2009)...andfluseasonuponus,it,smoreimportantthanevertoempl...oidillness. ,, "Weneedtobeproactivenotonlytokee...e,resick,"saidEileenFinerty,RN,MS,CIC(certifiedini...olandoccupationalhealthatHospitalforSpecialSurgery...asoneofthelowestinfectionratesofanyhospitalintheco...
(Date:11/26/2009)...ans living with diabetes will nearly double, incre... 2034. Over the same period, spending on diabetes ...36 billion, even with no increase in the prevalenc...of Chicago report in the December issue of Diabet...vered by Medicare will rise from 8.2 million to 14...
(Date:11/26/2009)... to strains or worse , , THURSDAY, Nov. ...with stuffing your turkey full to bursting, but yo...itcase as you pack for holiday trips. , More th...ital emergency rooms, doctors, offices, clinics an...uries, such as muscle strains, pulls and tears, ac...
Breaking Medicine News(10 mins):Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 2Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 3Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 2Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 3Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 4Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 2Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 3Health News:Diabetes cases to double and costs to triple by 2034 2Health News:Diabetes cases to double and costs to triple by 2034 3Health News:Pack Right for the Holidays to Avoid the ER 2
... Health Agency of Canada has reported that two tou..., leading to increased fears that the recent outbr...s in the country's tourist industry. The touri...dians traveling to the island to use anti-malarial...
...chers from Massachusetts and North Carolina have f...lised for treatment of conditions //that have resu...(COPD) such as emphysema, chronic bronchitis recei... treatment guidelines for this condition and none ...
...would be established in the near future for those ...nd HIV/AIDS //. Health Minister Mary Harney s...e introduction of a Bill to address insurance diff...patients especially women. These people suffe...
...Cancer Support of UK has taken a strong campaign a...onducted that said that in Scotland people spent//...al during treatment which is ?318 in Wales. Th...ents in Scotland and the South West can pay almost...
...a is a disease that spreads through mosquitoes. Ac...tion health officials there has been an increase i...bout 123 people are admitted in the hospital showi...ue. The disease is by far concentrated in North Ch...
...f five . Asthma-related deaths per year, in the U...ugs salmeterol or formoterol //. According to res...hese drugs should be taken off the market . Th... who inhaled the long-acting beta-agonists salmete...
Other Medicine News:Health News:Outbreak of Malaria to Lead to Loss in Tourist Industry 2Health News:COPD Patients In US Are Not Receiving 'Ideal Care' 2Health News:Inhaler Linked To Asthma Deaths 2Health News:Inhaler Linked To Asthma Deaths 3
Eppendorf Research Series 2100 Adjustable-volume Pipette, 20-200 l
...or for sub-microliter pipetting and beyond. Offers...adjustable. Features lPLUS, a direct-drive digital...le ejector buttons to fit large hands or tiny hand...ifferent lengths. Air-displacement mechanism. No r...
...bsystems was designed specifically to combine ergo...features such as the new fast dial system with .01...define this as a new leader in single channel pipe...a custom fit for different hand sizes. The new sho...
...tte is a synonym for pipetting accuracy, a smooth ...operating comfort. Its single, multifunctional but...ow-out as well as eject the tip. Product features...ccuracy and precision. Ejection sleeve can be rem...
Medicine Products: